Streetbeat News

Regulatory

BNBUSD

COIN

UNIUSD

Scott Johnsson of Van Buren Capital criticizes the Biden administration's regulatory actions on the cryptocurrency industry, including SEC enforcement against Coinbase, Binance, and Kraken, and the Federal Reserve's denial of Custodia's application. He argues these actions stifle industry growth and innovation.

Portfolio Pulse from Murtuza Merchant

May 31, 2024 | 2:13 pm

AMD

MSFT

NVDA

Zhipu AI, a Chinese AI company backed by Microsoft, has secured a $400 million investment from Saudi Arabia's Prosperity7, part of Aramco's venture capital arm. This investment values Zhipu AI at $3 billion and marks a significant foreign backing amid U.S. restrictions on AI investments in China. The geopolitical implications are notable, with the U.S. halting AI chip exports to the Middle East, affecting companies like Nvidia and AMD.

Portfolio Pulse from Anusuya Lahiri

May 31, 2024 | 2:11 pm

ZEAL

Zealand Pharma (NASDAQ: ZEAL) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its dasiglucagon solution for injection, intended for the treatment of severe hypoglycemia in diabetes patients. This recommendation is a significant step towards obtaining marketing authorization in Europe.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 2:11 pm

BTCUSD

DELL

ETHUSD

The article covers a range of topics including Ethereum facing major attacks and dominating May's cryptocurrency losses, Bitcoin spot ETFs seeing significant inflows, and various market and political updates. Key highlights include Ethereum's potential to hit $10K by year-end, Ripple CEO's predictions on crypto ETFs, and significant movements in tech stocks like Dell and Zscaler.

Portfolio Pulse from Akanksha Bakshi

May 31, 2024 | 2:07 pm

SPY

USO

The U.S. Treasury has issued new sanctions related to Iran, which could impact various sectors including energy and financial markets.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 2:06 pm

TAK

Takeda has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its recombinant ADAMTS13 enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP). If approved, it will be the first and only enzyme replacement therapy for cTTP in the European Union.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 1:59 pm

ESPO

FLUT

HERO

Flutter Entertainment Plc (NYSE:FLUT) shares initially traded lower in the premarket session on Friday following the announcement of CFO Paul Edgecliffe-Johnson's departure, but later reversed losses and traded higher. Rob Coldrake, the new CFO, will focus on the American market. The company is shifting its primary share listing from London to New York due to the growing U.S. market. Challenges include a revived shareholder lawsuit and a new tax on sports betting in Illinois. Flutter reported strong fiscal 2023 results with significant revenue and EBITDA growth. The stock has lost 4% in the last 12 months. Investors can also gain exposure to the sector via VanEck Video Gaming And ESports ETF (NASDAQ:ESPO) and Global X Video Games & Esports ETF (NASDAQ:HERO).

Portfolio Pulse from Anusuya Lahiri

May 31, 2024 | 1:53 pm

AMZN

The US National Highway Traffic Safety Administration (NHTSA) is seeking more details on crashes involving Zoox, a self-driving vehicle company owned by Amazon (AMZN). The agency is investigating the safety and performance of Zoox's autonomous vehicles.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 1:33 pm

GILD

Gilead Sciences Inc (NASDAQ:GILD) announced that its Phase 3 TROPiCS-04 study for Trodelvy in treating metastatic urothelial cancer did not meet its primary endpoint of overall survival. The study showed numerical improvement in overall survival favoring Trodelvy, but also a higher number of deaths due to adverse events compared to chemotherapy. Gilead will further investigate the data and discuss next steps with the FDA. GILD shares were trading lower by 2.23% premarket.

Portfolio Pulse from Vandana Singh

May 31, 2024 | 1:27 pm

REGN

SNY

The FDA has extended the review deadline for Regeneron and Sanofi's Dupixent for treating COPD to September 27, 2024. The extension follows the submission of additional efficacy analyses. The European Medicines Agency has also recommended approval of Dupixent for COPD in the EU.

Portfolio Pulse from Vandana Singh

May 31, 2024 | 1:23 pm